SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Completed · Phase 3 · Has a placebo group

Conditions studied: Endometriosis Related Pain

In brief

The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on dysmenorrhea and on nonmenstrual pelvic pain.

Key facts

Study ID
NCT03204318
Run by
Myovant Sciences GmbH
People needed
638
Starts
2017-12-07
Expected to finish
2021-04-08
Last updated by the study team
2021-06-28

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.